Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for BridgeBio Pharma, Inc. (BBIO : NSDQ)
 
 • Company Description   
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.

Number of Employees: 730

 
 • Price / Volume Information   
Yesterday's Closing Price: $51.21 Daily Weekly Monthly
20 Day Moving Average: 2,190,681 shares
Shares Outstanding: 191.17 (millions)
Market Capitalization: $9,789.76 (millions)
Beta: 1.25
52 Week High: $54.60
52 Week Low: $21.72
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 0.06% -1.70%
12 Week 28.03% 16.29%
Year To Date 86.63% 71.15%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
3160 PORTER DR. SUITE 250
-
PALO ALTO,CA 94304
USA		 ph: 650-391-9740
fax: -		 None http://www.bridgebio.com
 
 • General Corporate Information   
Officers
Neil Kumar - Chief Executive Officer; Director
Thomas Trimarchi - President; Chief Operating Officer
Maricel M. Apuli - Chief Accounting Officer
Eric Aguiar - Director
Jennifer E. Cook - Director

Peer Information
BridgeBio Pharma, Inc. (BGMR)
BridgeBio Pharma, Inc. (BBIO)
BridgeBio Pharma, Inc. (IPAH)
BridgeBio Pharma, Inc. (BRL)
BridgeBio Pharma, Inc. (BHC)
BridgeBio Pharma, Inc. (AKRXQ)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-GENERIC DRG
Sector: Medical
CUSIP: 10806X102
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 06/01/25
Next Expected EPS Date: 11/11/25
Share - Related Items
Shares Outstanding: 191.17
Most Recent Split Date: (:1)
Beta: 1.25
Market Capitalization: $9,789.76 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.69 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-3.28 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 11.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: 40.04% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 11/11/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: 41.52
EPS Growth
vs. Year Ago Period: 6.86%
vs. Previous Quarter: -7.95%
Sales Growth
vs. Year Ago Period: 4,999.86%
vs. Previous Quarter: -5.20%
ROE
06/30/25 - -
03/31/25 - -
12/31/24 - -
ROA
06/30/25 - -85.69
03/31/25 - -94.43
12/31/24 - -75.69
Current Ratio
06/30/25 - 5.19
03/31/25 - 4.57
12/31/24 - 4.67
Quick Ratio
06/30/25 - 5.08
03/31/25 - 4.54
12/31/24 - 4.67
Operating Margin
06/30/25 - -322.17
03/31/25 - -604.04
12/31/24 - -275.28
Net Margin
06/30/25 - -329.25
03/31/25 - -524.25
12/31/24 - -241.44
Pre-Tax Margin
06/30/25 - -331.52
03/31/25 - -530.27
12/31/24 - -244.34
Book Value
06/30/25 - -9.30
03/31/25 - -8.63
12/31/24 - -7.71
Inventory Turnover
06/30/25 - 1.61
03/31/25 - 5.99
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Capital
06/30/25 - -
03/31/25 - -
12/31/24 - -
 

Powered by Zacks Investment Research ©